Senior insider sale
Chief Executive Officer at CRISPR THERAPEUTICS AG — senior position signals high conviction
$5.20M
90K shares
What this filing means
KULKARNI SAMARTH plans to sell 90K shares of CRISPR THERAPEUTICS AG valued at approximately $5.20M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 1/22/2026ACC: 0001958244-26-000050
DirectorOfficer· Chief Executive Officer
Since Sep 2018
90K
Shares to sell
$5.20M
Approx. market value
60K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months2
Acquired as compensation -- Restricted Stock Awards
Compensation
10/16/2025
48.08KAcquired as compensation -- Restricted Stock Awards
Compensation
8/15/2025
11.92KTotal acquired60K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
10/16/2025 | Acquired as compensation -- Restricted Stock Awards Compensation | 48.08K | — |
8/15/2025 | Acquired as compensation -- Restricted Stock Awards Compensation | 11.92K | — |
| Total | 60K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
30K
Market value
$1.55M
1/20/2026
Planned — Approximate Date
NASDPlanned
Units to sell
60K
Market value
$3.65M
1/22/2026
Total
Units
90K
Value
$5.20M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
1/20/2026 | 30K | $1.55M | — | Completed |
| Planned — Approximate Date | ||||
1/22/2026 | 60K | $3.65M | NASD | Planned |
| Total | 90K | $5.20M | ||